With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Immunotherapy with checkpoint blockade induces rapid and durable immune control of
cancer in some patients and has driven a monumental shift in cancer treatment. Neoantigen …

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT),
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …

Background Findings of retrospective studies suggest that sorafenib maintenance post-
transplantation might reduce relapse in patients with FLT3 internal tandem duplication (FLT3 …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

We generated ex vivo drug-response and multiomics profiling data for a prospective series
of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision …

The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …